Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Management of Thyroid Eye Disease in the United Kingdom: A Multi-Centre Thyroid Eye Disease Audit
source: Orbit
year: 2017
authors: Mellington FE, Dayan CM, Dickinson AJ, Hickey JL, MacEwen CJ, McLaren J, Perros P, Rose GE, Uddin J, Vaidya B, Foley P, Lazarus JH, Mitchell A, Ezra DG
summary/abstract:This article aims to provide baseline data and highlight any major deficiencies in the current level of care provided for adult patients with thyroid eye disease (TED). We undertook a prospective, nonrandomized cross-sectional multicenter observational study. During a 3-month period June-August 2014, consecutive adult patients with TED who presented to nominated specialist eye clinics in the United Kingdom, completed a standardized questionnaire.
Main outcome measures were: demographics, time from diagnosis to referral to tertiary centre, time from referral to review in specialist eye clinic, management of thyroid dysfunction, radioiodine and provision of steroid prophylaxis, smoking, and TED classification. 91 patients (mean age 47.88 years) were included. Female-to-male ratio was 6:1. Mean time since first symptoms of TED = 27.92 (73.71) months; from first visit to any doctor with symptoms to diagnosis = 9.37 (26.03) months; from hyperthyroidism diagnosis to euthyroidism 12.45 (16.81) months. First, 13% had received radioiodine.
All those with active TED received prophylactic steroids. Seven patients who received radioiodine and did not have TED at the time went on to develop it. Then, 60% patients were current or ex-smokers. 63% current smokers had been offered smoking cessation advice. 65% patients had active TED; 4% had sight-threatening TED. A large proportion of patients (54%) were unaware of their thyroid status. Not enough patients are being provided with smoking cessation advice and information on the impact of smoking on TED and control of thyroid function.
organization: Moorfields Eye Hospital, UK; Cardiff University School of Medicine, UK; Newcastle upon Tyne Hospitals NHS Foundation Trust, UK; British Thyroid Foundation, UK; Ninewells Hospital, UK; Thyroid Eye Disease Charitable Trust, UK; UCL Institute of Ophthalmology Biomedical Research Centre for Ophthalmology, UK; Royal Devon and Exeter Hospital and University of Exeter Medical School, UKDOI: 10.1080/01676830.2017.1280057
read more
Related Content
-
Graves’ OrbitopathyEpidemiology: Eye complications occur i...
-
Radiotherapy for Active Thyroid Eye DiseasePurpose: To critically review the publi...
-
Piezosurgery in Modified Pterional Orbital Decompression Surgery in Graves’ DiseaseObjective: Piezosurgery uses microvibra...
-
James A. Katowitz, MDJames A. Katowitz, MD, is an attending s...
-
Prevent Blindness Art Therapy ProgramPrevent Blindness is excited to announce...
-
Flaum Eye Institute at the University of Rochester Medical CenterMultidisciplinary collaborations are a k...
-
Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presen...Horizon Therapeutics plc today announced...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.